GL
Gilles Lambert
University of Reunion Island, Nantes Université, Sorbonne Université, The Heart Research Institute
Research areas: Medicine · Cardiology and Cardiovascular Medicine · Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism · Lipid metabolism and disorders
0000-0001-5632-0685
Employment
-
Université de la Réunion Professor2015 - Present
-
Nantes Université Associate Professor (Faculté de Médecine)2010 - 2015
-
Heart Research Institute Senior Research Officer2006 - 2010
-
Nantes Université Assistant Professor2002 - 2006
-
National Institutes of Health Post Doctoral Fellow1998 - 2002
Education
-
Université Paris-Sorbonne PhD - Doctorat1994 - 1998
Projects & Funding
-
Personalized Medicine for Familial Hypercholesterolemia (PERMEDFH) CAIXA RESEARCH FOUNDATION2025 - 2026
-
PCSK9 in the Peripheral Nervous System Agence Nationale de la Recherche2025 - 2028
-
KRINGLE2 Agence Nationale de la Recherche2021 - 2024
-
Regulation génique de la LPA Fondation de France2019 - 2022
-
Cholesterol Personalized Innovation (CHOPIN) Agence Nationale de la Recherche2016 - 2021
-
Bénéfices Cardiovasculaires d'une nouvelle cible thérapeutique hypolipémiante Agence Nationale de la Recherche2012 - 2015
-
Cardiovascular benefits of PCSK9 inhibition National Health and Medical Research Council2011 - 2013
-
Assessment of PCSK9 function in familial hypercholesterolemia National Heart Foundation of Australia2009 - 2010
Publications (101)
- Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL Trial Save
- The molecular structure of LDL has finally been elucidated Save
- Why has the “Lp(a) receptor” proven so elusive? Save
- Lipoprotein(a) Save
- Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors Save
- PCSK9 and the nervous system: a no-brainer? Save
- A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo Save
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement Save
- Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms Save
- A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants Save
- PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Hyperglycemic Mice Increases the Risk of Hemorrhagic Transformation of Ischemic Stroke Save
- Heart to heart with PCSK9 Save
- Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. Save
- VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Save
- A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. Save
- Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. Save
- A transgenic mouse model reproduces human hereditary systemic amyloidosis. Save
- Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report. Save
- PCSK9 inhibition for autosomal recessive hypercholesterolemia. Save
- PCSK9: from biology to clinical applications. Save